Evidence map›Paper›PMID 37390387›Full record

ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2023

Reply to Z.R. McCaw et al.

Jason E Farrar, Megan Othus, Yi-Cheng Wang, Todd A Alonzo, Soheil Meshinchi

Abstract readLetterComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Jason E FarrarJason E. Farrar, MD, Arkansas Children's Research Institute and Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, AR; Megan Othus, PhD, Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA; Yi-Cheng Wang, MS, Children's Oncology Group, Monrovia, CA; Todd A. Alonzo, PhD, Children's Oncology Group, Monrovia, CA, Department of Population and Public Health Sciences, University of Southern California, Los Angeles, CA; and Soheil Meshinchi, MD, PhD, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, Department of Pediatrics, University of Washington, Seattle, WA.ORCID 0000-0003-2148-5839
Megan OthusJason E. Farrar, MD, Arkansas Children's Research Institute and Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, AR; Megan Othus, PhD, Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA; Yi-Cheng Wang, MS, Children's Oncology Group, Monrovia, CA; Todd A. Alonzo, PhD, Children's Oncology Group, Monrovia, CA, Department of Population and Public Health Sciences, University of Southern California, Los Angeles, CA; and Soheil Meshinchi, MD, PhD, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, Department of Pediatrics, University of Washington, Seattle, WA.ORCID 0000-0001-8176-6371
Yi-Cheng WangJason E. Farrar, MD, Arkansas Children's Research Institute and Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, AR; Megan Othus, PhD, Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA; Yi-Cheng Wang, MS, Children's Oncology Group, Monrovia, CA; Todd A. Alonzo, PhD, Children's Oncology Group, Monrovia, CA, Department of Population and Public Health Sciences, University of Southern California, Los Angeles, CA; and Soheil Meshinchi, MD, PhD, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, Department of Pediatrics, University of Washington, Seattle, WA.
Todd A AlonzoJason E. Farrar, MD, Arkansas Children's Research Institute and Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, AR; Megan Othus, PhD, Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA; Yi-Cheng Wang, MS, Children's Oncology Group, Monrovia, CA; Todd A. Alonzo, PhD, Children's Oncology Group, Monrovia, CA, Department of Population and Public Health Sciences, University of Southern California, Los Angeles, CA; and Soheil Meshinchi, MD, PhD, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, Department of Pediatrics, University of Washington, Seattle, WA.
Soheil MeshinchiJason E. Farrar, MD, Arkansas Children's Research Institute and Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, AR; Megan Othus, PhD, Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA; Yi-Cheng Wang, MS, Children's Oncology Group, Monrovia, CA; Todd A. Alonzo, PhD, Children's Oncology Group, Monrovia, CA, Department of Population and Public Health Sciences, University of Southern California, Los Angeles, CA; and Soheil Meshinchi, MD, PhD, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, Department of Pediatrics, University of Washington, Seattle, WA.

Funding

NCTN BIQSFP ANBL1531 (NRT)U10CA180886 · NCI · PUBLIC HEALTH INSTITUTE · PI Douglas S. Hawkins · 2014 to 2026
$390.6M
SWOG Network Group Operations Center of the NCTNU10CA180888 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI PRIMO N. LARA · 2014 to 2026
$152.1M
COG SDMC - Statistics CoreU10CA180899 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI TODD A ALONZO · 2014 to 2026
$132.8M
SWOG Statistics & Data Management Center complex - extension supplement for GY06U10CA180819 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Michael L. LeBlanc · 2014 to 2026
$115.2M
COG U24 Funding 2026-2027U24CA196173 · NCI · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI Mignon Lee-Cheun Loh, Nilsa Del Carmen Ramirez Milan · 2015 to 2026
$62.5M
Translational Regulation in Normal Erythropoiesis and Diamond Blackfan AnemiaP20GM121293 · NIGMS · ARKANSAS CHILDREN'S HOSPITAL RES INST · PI Alan Tackett, Sean D. Taverna · 2017 to 2026
$27.6M
Biology/prognostic implications of Flt3 mutations in AMLR01CA114563 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI MESHINCHI, SOHEIL · 2005 to 2016
$4.4M
Novel Biomarkers to Risk-Stratify AML Patients with NPM1^Pos/FLT3-IT^Neg GenotypeR01CA190661 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI STIREWALT, DEREK L · 2016 to 2020
$2.7M
Discovery and Optimization of AML Prognostic BiomarkersR01CA160872 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI STIREWALT, DEREK L · 2012 to 2016
$2.5M
NCI NIH HHS R01 CA114563NCI NIH HHS R01 CA160872NCI NIH HHS R01 CA190661NCI NIH HHS U10 CA180819NCI NIH HHS U10 CA180886NCI NIH HHS U10 CA180888NCI NIH HHS U10 CA180899NCI NIH HHS U24 CA196173NIGMS NIH HHS P20 GM121293
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID37390387
PMCPMC10522099

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.